Search
Displaying results 61 to 70 of 1436.
Junior Research / Technology / Clinician-Scientist Group Leaders (m/f/d)
The HZI, is offering positions for Junior Research / Technology / Clinician-Scientist Group Leaders (m/f/d) in the field of infection research (with W1-professorship and tenure options).
Transfer of Knowledge
Transfer of Knowledge The HZI's research program places particular emphasis on the effective transfer of research results into clinical and industrial applications . In addition, the transfer of knowledge to society also plays a major role for us. The…
Innovative Organoid Research
Organoids are miniature models of human organs cultivated from stem cells in laboratory settings. These delicate tissue structures mimic the three-dimensional architecture and function of real organs, offering researchers a unique opportunity to enhance their understanding of biological processes. Our aim is to advance the development of highly complex organoids incorporating immune cells and vessels. By doing so, we establish a platform, especially for investigating infections, conducting vaccine tests, and innovating therapeutic approaches.
Synthetic biology of microbial natural products
The Bozhüyük group focuses on bacterial natural products, with unique structures and bioactive properties. The group studies modular assembly lines like polyketide synthases (PKSs) and non-ribosomal peptide synthetases (NRPSs), which produce many essential clinical agents – but are especially valuable to develop new anti-infectives. This group is located at the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) .
Proteome Analytics
Pathogenic bacteria and viruses utilize and manipulate cellular processes of our immune system. The identification of protein functions in the human immune system that decisively control the progression of infections constitutes the central aim of the research group Cellular Proteomics at the HZI.
Microbial Drugs
The majority of the medically important antibiotic drugs are derived from secondary metabolites, which are produced by bacteria and filamentous fungi. Despite intensive world-wide efforts using alternative approaches, no other concept could so far surpass the historically successful strategy to exploit biologically active natural products as candidates for anti-infective drugs. The recently observed, increasing resistance of the human pathogens against antibiotics has prompted us to intensify our search for novel lead structures from microorganisms and fungi, which can be used as anti-infective drugs.
Laboratory of Transmission Immunology
Transmission of viruses is only possible during a specific time frame after infection: we can call this the “window of transmission”. A major gap in mitigating (e.g., airborne) transmission and closing this window quickly is the lack of understanding of critical immune determinants of efficient transmission. To be able to close the window of transmission through the design of better mitigation strategies, we develop a mechanistic understanding of the spatial and longitudinal interplay between virus tropism, innate and adaptive immune responses, changes in host physiology, and exhalation or shedding of infectious virus in droplets or fluids.
Integrative Informatics for Infection Biology
Recent years have seen accelerating development of high-throughput technologies in infection biology. Now, thousands of genetic loci can be simultaneously interrogated in a single experiment, providing an array of measurements of transcription, translation, regulatory interactions, and fitness effects. The bottleneck in advancing our understanding of pathogens now lies in moving from hypothesis-free screening through data integration to hypothesis generation. We develop new statistical, computational, and visualization approaches to overcome this bottleneck in the interpretation of complex post-genomic data. This group is located at the Helmholtz Institute for RNA-based Infection Research (HIRI).
Epidemiology and ecology of antimicrobial resistance
Due to the interconnectedness between humans, animals and the environment, as well as the rapid potential for antimicrobial resistance to spread between bacterial species, we need a One Health approach to adequately address the threat of antibiotic resistance. This department is based at the Helmholtz Institute for One Health .
